SF0083 - Wyoming Pharmacy Act amendments.

 

2001

State of Wyoming

01LSO-0175.E1

ENGROSSED

 

 

 

SENATE FILE NO.  SF0083

 

 

Wyoming Pharmacy Act amendments.

 

Sponsored by:

 

 

A BILL

 

for

 

 1  AN ACT relating to the Wyoming Pharmacy Act; amending and
 2  clarifying provisions with respect to dispensing of drugs;
 3  amending examination fees as specified; repealing
 4  conflicting provisions; and providing for an effective
 5  date.

 6 

 7  Be It Enacted by the Legislature of the State of Wyoming:

 8 

 9         Section 1.  W.S. 33-24-101(c)(i) and (viii),
10  33-24-112(a)(i), 33-24-121(a), 33-24-136(c),
11  33-24-147(a)(ii), 33-24-148(b) and by creating a new
12  subsection (g) and 33-24-149(a) and (d) are amended to
13  read:

14 

15         33-24-101.  Short title; definition.

16 

 

Page  1

 

 

 

 1         (c)  As used in this act, "unprofessional conduct"
 2  means:

 3 

 4              (i)  Substituting Dispensing a drug or brand of
 5  drug in filling a prescription which differs from that
 6  specified by the prescription without authority of the
 7  issuer of the prescription;

 8 

 9              (viii)  Filling a prescription with drugs which
10  may have lost their effectiveness when the drugs are
11  acquired as indicated by the a drug that is past the
12  expiration date provided by the manufacturer or supplier of
13  the drug or other competent authority;

14 

15         33-24-112.  Fees for examinations, reexaminations,
16  license renewals and registration renewals; late fees.

17 

18         (a)  The board shall determine each year the fees to
19  be collected for examinations, reexaminations, license
20  renewals and registration renewals based upon annual normal
21  operating expenses, including late fees to be collected for
22  failure to pay a license or renewal fee by the deadline
23  established by the board, provided that:

24 

 

Page  2

 

 

 

 1              (i)  Examination and reexamination fees shall not
 2  exceed five hundred dollars ($500.00) plus the amount
 3  charged by the National Association of Boards of Pharmacy
 4  to take the examinations;

 5 

 6         33-24-121.  Renewal license certificate; late fee;
 7  expiration upon failure to renew; reinstatement; continuing
 8  professional education requirement for renewal; reduction
 9  or exception determined by board.

10 

11         (a)  On or before December 31 of each year, any person
12  except interns practicing pharmacy in this state and any
13  pharmacist licensed to practice pharmacy in this state
14  shall transmit to the secretary of the board his signature,
15  registration number and address together with proof of
16  compliance with subsection (d) of this section, and the
17  annual fee determined by the board and the relevant
18  information pertaining to criminal, substance abuse,
19  professional liability and licensure history. Upon receipt
20  and compliance with all requirements, the secretary shall
21  issue a renewal license certificate.

22 

 

Page  3

 

 

 

 1         33-24-136.  Filing written memorandum of prescription;
 2  labels generally; prescription defined; counseling and
 3  patient profiles.

 4 

 5         (c)  Pharmacists shall offer to and shall counsel
 6  medicaid patients if requested, concerning and in
 7  conjunction with drugs dispensed pursuant to a new
 8  prescription.

 9 

10         33-24-147.  Definitions.

11 

12         (a)  As used in this act:

13 

14              (ii)  "Generically equivalent drug" means a drug
15  that contains identical active ingredients in the identical
16  dosage forms, but not necessarily containing the same
17  inactive ingredients, that meet the identical compendial or
18  other applicable standards of identity, strength, quality
19  and purity, including potency, and, where applicable,
20  content uniformity, disintegration times or dissolution
21  rates, as the prescribed brand name drug, and, if
22  applicable, the manufacturer or distributor holds either an
23  approved new drug application or an approved abbreviated
24  new drug application unless other approval by law or from

Page  4

 

 

 

 1  the Federal Food and Drug Administration is required. No
 2  drug is considered a generically equivalent drug if it has
 3  been listed by the Federal Food and Drug Administration as
 4  having proven bioequivalence problems A generically
 5  equivalent drug shall bear an "AB" or higher rating in the
 6  Federal Food and Drug Administration Approved Drug Products
 7  with Therapeutic Equivalence Evaluations;

 8 

 9         33-24-148.  Conditions for drug substitution.

10 

11         (b)  Except as limited by subsection (c) of this
12  section and W.S. 33-24-149(b) or when the practitioner has
13  clearly indicated substitution is not permitted, a
14  pharmacist may substitute a drug product with the same
15  generic name in the identical strength, quantity, dose and
16  dosage form as the prescribed drug, if in the pharmacist's
17  professional opinion the drug substituted is
18  therapeutically equivalent provided the substituted drug
19  meets all requirements specified in W.S. 33-24-147(a)(ii).

20 

21         (g)  When a practitioner orally communicates a
22  prescription and prohibits a generic substitution, the
23  pharmacist shall make reasonable efforts to obtain a
24  written prescription from the practitioner with the phrase

Page  5

 

 

 

 1  "brand medically necessary" written on the face of the
 2  prescription in his own handwriting.

 3 

 4         33-24-149.  Drug substitution procedures.

 5 

 6         (a)  A pharmacist who receives a prescription for a
 7  brand name dangerous drug may dispense any generically
 8  equivalent drug of the brand name dangerous drug
 9  prescribed, when an authorization for substitution is given
10  unless the prescribing practitioner has clearly indicated
11  substitution is not permitted, if the drug to be dispensed
12  has a lower, regular and customary retail price than the
13  brand name dangerous drug prescribed, as provided in W.S.
14  33-24-148.

15 

16         (d)  The national drug code number or the name of the
17  manufacturer or distributor of the generic drug dispensed
18  shall be noted on the prescription memorandum by the
19  pharmacist.

20 

21         Section 2.  W.S. 33-24-148(a), (c), (d) and (f) is
22  repealed.

23 

 

Page  6

 

 

 

 1         Section 3.  This act is effective immediately upon
 2  completion of all acts necessary for a bill to become law
 3  as provided by Article 4, Section 8 of the Wyoming
 4  Constitution.

 5 

 6                         (END)

 

Page  7